Elysium Therapeutics

OH - AkronBiotechnology1 H-1B visas (FY2023)

Focus: Elysium Therapeutics is a biotechnology company headquartered in Akron, OH, focused on abuse-deterrent opioids and a diverse pipeline spanning neurology, infectious diseases, nephrology, metabolic diseases, and respiratory indications.

Neurology Infectious Diseases Nephrology Metabolic Diseases

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Elysium Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Elysium Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

20 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Group 1 NRPT

Fatty Liver

N/A

Clinical Trials (1)

NCT03513523Study to Assess the Relationship Between Daily Dosing of NRPT and Changes in Liver Fat in Healthy Volunteers

N/A

Help build intelligence for Elysium Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline across 5+ therapeutic areas including high-unmet-need areas like ALS, Huntington's, and aging biology
Early-stage platform with potential to shape abuse-deterrent opioid market—a regulated, high-impact segment
Active clinical trial portfolio (18 trials across Phase 1-2) with near-term data readouts likely to drive clinical milestones

Watch Out For

No marketed products or revenue—entirely pre-revenue biotech with unproven commercial viability
Extremely limited hiring signal (zero active job postings) suggests company may be very small, under-resourced, or dormant operationally
Pipeline heavily skewed toward early-stage (3 Phase 1, 4 Phase 2, 0 Phase 3)—long runway to regulatory approval and meaningful career impact

Generated by Claude from Elysium Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EH301

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT03489200EH301 for the Treatment of ALS

N/A

EH301

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT04562831The NO-ALS Study: A Trial of Nicotinamide/Pterostilbene Supplement in ALS.

N/A

EH301

Amyotrophic Lateral Sclerosis

N/A

Clinical Trials (1)

NCT05095571A Trial of Nicotinamide/Pterostilbene Supplement in ALS: The NO-ALS Extension Study

N/A

Nicotinamide Riboside

COPD

N/A

Clinical Trials (1)

NCT04990869Inflammation in COPD and the Effect of Nicotinamide Riboside

N/A

BASIS™

Menopause

N/A

Clinical Trials (1)

NCT04841499Effects of a Seven-day BASIS™ Supplementation on Menopausal Syndromes and Measurements of the Urinary Vitamin B3 and Estradiol Levels in Pre-, Peri- and Post-menopause

N/A

Surveys

Biological Aging

N/A

Clinical Trials (1)

NCT06333301Translational Initiative to Map Epigenetics in Sleep

N/A

Biomarker study

Epigenetics

N/A

Clinical Trials (1)

NCT04220658Biomarker Study to Evaluate Correlations Between Epigenetic Aging and NAD+ Levels in Healthy Volunteers